Halozyme Therapeutics, Inc. vs. Maze Therapeutics, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$111.45 -0.89%
VS MAZEMaze Therapeutics, Inc. Common Stock
$28.38 +26.75%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | MAZE | |
|---|---|---|
| Market Cap | $12.76 billion | $1.24 billion |
| Revenue (TTM) | $1.66 billion | $20.00 million |
| Net Income (TTM) | $413.60 million | $-133,590,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | MAZE | |
|---|---|---|
| P/E Ratio | 32.49 | — |
| Price / Book | 88.91 | 2.74 |
| Price / Sales | 7.67 | 62.19 |
HALO and MAZE split the valuation factors evenly.
Profitability
| HALO | MAZE | |
|---|---|---|
| Net Margin | 24.86% | -667.95% |
| Return on Equity | 288.13% | -29.48% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | MAZE | |
|---|---|---|
| Short Interest | 9.79% | 2.15% |
MAZE leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, MAZE overview, MAZE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.